Anlotinib Recruiting Phase 2 Trials for Hepatocellular,Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02809534A Study of Anlotinib in Patients With Hepatocellular Carcinoma